Navigation Links
Frost & Sullivan Global Product Line Strategy of the Year Award Presented to Xenemetrix
Date:10/12/2010

MOUNTAIN VIEW, Calif., Oct. 12 /PRNewswire/ -- Based on its recent research on the EDXRF Analyzers market, Frost & Sullivan presents Xenemetrix, Inc. with the 2010 Global Product Line Strategy of the Year Award.

(Logo:  http://photos.prnewswire.com/prnh/20081117/FSLOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

"A leading designer, manufacturer, and distributor of Energy Dispersive X-ray Fluorescence (EDXRF) systems, Xenemetrix, Inc. offers an extensive range of high quality, leading-edge laboratory, bench top and mobile analyzer models," states Frost & Sullivan Industry Manager Sujan Sami. "Xenemetrix's products offer value to customers in terms of logistics, suitability for a specific application, ease of use and operability."

The company's laboratory EDXRF analyzers - EX-6600 LN/PD, EX-6600 SDD, EX-3600 LN/PD and EX-6600 AF - are designed for precision, accuracy and durability, which is paramount for field and lab elemental analysis systems. The company's bench-top models range from cost effective analyzers to high-power ones, like the X-Cite, RoHS Vision, X-PMA, X-Calibur PD and X-Calibur SDD.  Xenemetrix's product portfolio also covers mobile analyzers, including the S-Mobile, S-Mobile SDD and S-Mobile-ULS.

In addition, the geological mapping solution (a combination of S-Mobile and EX-6600 products) is set to bolster the company's market position. This technologically advanced solution finds application with mineralogical specimens for characterizing their content from precious metals to base metals in order to verify different types of compositions.

"The company has built on its customer base through the strategic acquisition of Jordan Valley Semiconductors' analytical division in June 2008," states Sami. "This acquisition offered superior value
'/>"/>

SOURCE Frost & Sullivan
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Frost & Sullivan Acknowledges Accelrys for Scientific Informatics Solution
2. Low Installation Rates in Retail Pharmacies Across Europe Increase the Growth Potential of the Pharmacy Automation Systems Market, Finds Frost & Sullivan
3. Frost & Sullivan Applauds the Lodox Statscan Critical Imaging System for Outperforming All Competing Products
4. U.S. Ambulatory Electronic Health Record Market Presents Significant Opportunities and Risks for Vendors, Finds Frost & Sullivan
5. Increasing Potential for RIS-driven PACS Modules in Europe, Finds Frost & Sullivan
6. Frost & Sullivan Recognizes QRxPharma for Innovative Pain Relief Product MoxDuo
7. Rising Burden of Diseases Drives the Pharmaceutical Industry in East Africa, Says Frost & Sullivan
8. Frost & Sullivan: Innovative Products and Technologies Strengthen U.S. Spinal Surgery Market
9. Frost & Sullivan Recognizes Timoptic(R) (timolol maleate) as Best Brand Name Beta Blocker for Glaucoma: Timoptic Brand is Highest Rated in Survey of Ophthalmologists
10. Frost & Sullivan Recognizes Holst Centre and imec for Its Path Breaking Wearable Energy Harvester Technology
11. Frost & Sullivan Recognizes Japan Stent Technology for Its Pioneering Coronary Stent Design
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... 2014   ViaDerma, Inc. (OTCQB: VDRM), ... products to market, has recently released a revolutionary ... a topical liquid tetracycline-based antibiotic that uses a ... oral medication active ingredients into topical drugs. The ... antibiotic to help prevent skin infection in minor ...
(Date:10/30/2014)... CVS Health (NYSE: CVS ) announced ... leading regional health systems to enhance access to high-quality, affordable ... Baptist Health System in Alabama ; Community ... Pennsylvania , Northwest Medical Center, including Oro ... Healthcare in Tennessee ; and Premier Health ...
(Date:10/30/2014)... Kingdom , Oct. 30, 2014 Molecular ... CBRX ) and Maryland ... developers with improved efficiency during clinical development that will ... next week. This partnership extends ... platform, which it launched earlier this month. The company ...
Breaking Medicine Technology:ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 2CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 3CVS Health Announces New Clinical Affiliations with Leading Regional Health Systems 4Molecular Profiles To Launch US Strategic Alliance At AAPS 2Molecular Profiles To Launch US Strategic Alliance At AAPS 3
... , March 11 Watson Pharmaceuticals, Inc. ... Food and Drug Administration (FDA) approval of TRELSTAR® 22.5 ... formulation of TRELSTAR®, a proven, simple and effective palliative ... launch, TRELSTAR® 22.5 mg is the first and only ...
... SiteJabber.com , a leading consumer protection service which helps people avoid fraudulent websites and find good sites, and LegitScript.com ... websites and avoid fraudulent ones. , ... ... ...
Cached Medicine Technology:FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 2FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 3FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 4FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 5FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 6FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 7FDA Approves Watson's TRELSTAR(R) 22.5 mg, the First and Only 6-Month Intramuscular GnRH Agonist for the Palliative Treatment of Advanced Prostate Cancer 8SiteJabber & LegitScript Launch Partnership to Improve Transparency Around Online Pharmacies 2SiteJabber & LegitScript Launch Partnership to Improve Transparency Around Online Pharmacies 3
(Date:10/30/2014)... of data from an institutional patient registry on ... control, 79 percent of tumors, for medically inoperable, ... from 2003 to 2012, according to research presented ... Thoracic Oncology. The Symposium is sponsored by the ... Society for Radiation Oncology (ASTRO), the International Association ...
(Date:10/30/2014)... WHAT: , A mathematical model developed by NIH grantees ... daily to prevent HIV infection via vaginal sex, whereas ... HIV infection via anal sex. This finding helps explain ... or PrEP, in women failed to show efficacy. Participants ... trials of Truvada and tenofovir (another antiretroviral) for HIV ...
(Date:10/30/2014)... Graphics, coding, typography and search engine optimization– ... of web design and require thorough knowledge to create ... to create a website can be as easy as ... reviews and Facebook posts all accumulate on a multiple ... evolution of how a business can develop a website," ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 Five months ... Hodgkinson Street LLC announces new branding and a ... Street Mepham . After David Mepham’s promotion to name ... brand and website to include Mepham’s name and better ... malpractice and mediation firm, the decision to implement new ...
(Date:10/30/2014)... 2014 Radio listeners who indicate use ... the impact of traditional radio commercials and have overwhelmingly ... to influence a purchasing decision. , Those are some ... conducted by radio marketing company CRN International. The research ... results of respondents who indicated they have purchased or ...
Breaking Medicine News(10 mins):Health News:Sustained local control for medically inoperable, early stage lung cancer patients 2Health News:Sustained local control for medically inoperable, early stage lung cancer patients 3Health News:Model by NIH grantees explains why HIV prevention dosing differs by sex 2Health News:Facebook Websites In Thirty-Seconds 2Health News:Hodgkinson Street Mepham Rebrands 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 3
... The Lupus Foundation of,America (LFA) is ... in grant funding,for basic, clinical, or translational ... fatal autoimmune disease. The purposes of the,studies ... novel,approaches; and develop experimental prototypes. Grants will ...
... Council (ACC) today sent a letter to FDA ... review of the safety of bisphenol A,in food ... study regarding bisphenol A is well,documented and well ... the safety and use of polycarbonate plastic and ...
... Mass., April 17 Inverness Medical,Innovations, Inc. (Amex: ... point-of-care,diagnostic products, today announced that it will release ... 2008. The Company will also host a,conference call ... date to,discuss these results and other corporate matters. ...
... They,re more disruptive than long hours, night shifts or job ... Common job-related problems such as conflicts with bosses or co-workers ... insecurity to cause poor sleep. , That,s the conclusion of ... from two surveys of about 2,300 U.S. adults who were ...
... Pennsylvania School of Medicine are developing a novel approach ... as amyotrophic lateral sclerosis (ALS), or Lou Gehrig,s disease, ... mutations have been found in a disease protein called ... of frontotemporal dementia (FTD). , We,ve created a ...
... KIRKLAND, Wash., April 17 For health reasons, Americans,in ... than they think,according to Denise Gott, Vice Chairperson of ... long term care insurance agencies.,"The sudden need for long ... "and they,re vulnerable on two fronts, not just one, ...
Cached Medicine News:Health News:Lupus Foundation of America Seeks Funding Proposals for Research Studies on Childhood Lupus, Nervous System Involvement, and More 2Health News:ACC Calls on FDA to Update Review of Bisphenol A 2Health News:ACC Calls on FDA to Update Review of Bisphenol A 3Health News:Inverness Medical Innovations Schedules Conference Call for 10:00 a.m. ET April 24, 2008 to Discuss First Quarter 2008 Results 2Health News:Work Conflicts Can Do a Job on Your Sleep 2Health News:Penn researchers find potential in yeast for selecting Lou Gehrig's disease drugs 2Health News:Today's Working Adults Face Long Term Care 'Double Whammy,' Says Denise Gott, Spokesperson for LTC Financial Partners, LLC 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: